Jan. 28 at 11:24 AM
$DHR
Danaher reports Q4 adjusted EPS
$2.23, consensus
$2.19
Reports Q4 revenue
$6.84B, consensus
$6.81B. Rainer Blair, president and CEO, stated, "We delivered a strong finish to the year with better-than-expected performance across our portfolio. We were particularly encouraged by continued strength in our bioprocessing business, along with improved momentum in Diagnostics and Life Sciences. Our teams' disciplined execution also enabled us to exceed our fourth quarter margin, earnings, and cash flow expectations.
Danaher sees Q1 revenue up low-single digit percent
Blair continued, "Looking ahead, we expect the gradual improvement in our end markets we saw through 2025 to continue, and we believe the combination of our differentiated portfolio, the power of the Danaher Business System, and the strength of our balance sheet positions Danaher for long-term value creation as we move into 2026 and beyond."
Danaher sees FY26 EPS
$8.35-
$8.50, consensus
$8.42
Sees FY26 revenue up 3%-6%. The company said, "For full year 2026, the Company expects that non-GAAP core revenue will increase in the 3% to 6% range year-over-year. The Company is also initiating full year adjusted diluted net earnings per common share guidance in the range of
$8.35 to
$8.50."
